Interestingly, Roslind et al. claimed that serum concentrations of YKL-40 may provide a more consistent biomarker of a specific patient’s disease progression as intratumoral YKL-40 expression can vary across a single breast cancer nodule [16]. This evidence concerns the gene CHI3L1 and breast carcinoma.